---
title: "Final Update Antipsychotics Project"
subtitle: "I´m so glad &#x1F602;&#x1F44F;"
format: 
  revealjs:
    theme: [default, custom.scss]
    slide-number: true
incremental: true
editor: source
---

## Differentially Methylated Regions <br> associated with antipsychotic treatment <br> <br> <br> <br> <br> Martens Summer Seminar <br> June 17, 2024 {background-color="black" background-image="img/summerFlowers.jpg" background-size="cover" background-opacity="0.7"}

---

## Psychotic Disorders<br>

:::: columns
::: {.column width="30%"}
![]
:::

::: {.column width="70%"}
<p>[SCZ, BPD, MDD]{.highlight}</p>

<br> Prevalence in Norway \~ 1.6 % (Helsedirektoratet, 2019, Report part III) <br><br>  <br>   

:::

::: footer
Martens Summer Seminar June 17, 2024
:::
---

## Antipsychotics <br>

::: {.nonincremental}

-  Acute phase: Often very effective<br>
-  Long term: health problems, cognitive decline,<br> reduced effect<br>
-  Efficacy: D2/D3 receptor antagonism <br>
-  Side effects: multiple receptor targets<br>
-  Therapeutic advances target dopamine/glutamate 

:::


::: footer
Martens Group Retreat

:::


---

## The Synapse in Psychosis





::: footer
Figure: 
:::

---





---


## The Environment and DNAm

{fig-align="center"}

::: footer
Fig. adapted from Tzika, Dreker, Imhof, 2018, ***Frontiers in Genetics***
:::

---


## The Path to Methylation 

{fig-align="center"}




---


## DNA Methylation & Antipsychotics <br> <br>

<p>[Olanzapine, Quetiapine, Risperidone]{.highlight}</p>

::: {.nonincremental}
 

-  Aim 1: To identify common and specific effects on DNA methylation mediated by these APs.

-  Aim 2: Will characterizing variation in methylation contribute to Aim 1? 

:::

::: footer
Martens Summer Seminar June 17, 2024
:::


---


## Methods: Sample Selection {.nostretch}

{width="45%" fig-align="center"}

---

## Methods: Models

Adjustment for both: <br> Age + Sex + Smoking Score + Diagnosis + Technical + eCells

:::: columns
::: {.column width="50%"}
<br>

<p>[Common Effects]{.highlight}</p>

<br>

Quantitative (n=136) <br> <br>

DNAm \~ AP serum values

:::

::: {.column width="50%"}
<br>

<p>[Specific Effects]{.highlight}</p>

<br>

Categorical (n=259) <br> <br>

DNAm \~ AP vs. <br> (2 APs + Med-free)
:::

::::

---

## EWAS and Regional Analyses

:::: columns
::: {.column width="50%"}
<p>[Differentially Methylated (DMRs)]{.highlight}</p>

<br> * Detects mean difference between tissues <br><br> * Parameters: 500 bp, <br> min. 4 CpGs, FDR 0.05
:::

::: {.column width="50%"}
<p>[Variably Methylated (VMRs)]{.highlight}</p>

<br> <br> * Detects difference in variance within a tissue <br><br> * Parameters: 1000 bp, <br> min. 10 CpGs, C2, FDR 0.05
:::

::::

::: footer
R packages: DMRs - *dmrff*, Suderman, 2018,
:::

---

## Results: Common Effects - DMRs

{fig-align="center"}

---

## Results: *SHANK2* <br>

SH3 and multiple ankyrin repeat domains 2 <br><br>

Synaptic Gene Ontologies Database

<p>[GO terms:]{.highlight}</p> 

::: {.nonincremental}

-  postsynaptic density (GO:0014069) <br> 
-  regulation of postsynapse organization (GO:0099175) <br> 
-  structural constituent of postsynaptic density (GO:0098919) <br> <br> 

:::



::: footer

https://www.syngoportal.org/

:::

---

## Results: The *SHANK2* DMR

![](img/SerumValues_SHANK2.png)

---

## Results: Common Effects - VMRs<br><br>



:::: footer
Martens Summer Seminar June 17, 2024
:::: 

---

<p>[*TNXB* (Tenascin-XB)]{.highlight}</p> chr6 MHC (class III region)

:::: {layout-ncol=1}




![](img/TNXB_ref.png)


::::

---

## Results: Specific Effects - DMRs<br>

![]{width="60%"}

---

## Results: Specific Effects - VMRs<br>

!{width="60%"}

---

## Conclusion

::: {.incremental}

-  The common effects of APs on ***SHANK2*** expression and glutamate receptor function may be mediated by DNAm. 

-  Identification of the specific effects may need larger sample sizes.  

-  GxE interactions are implicated in up to 75% of VMRs (Epigenomics of Common Diseases 2023). 

:::

::: footer
Martens Summer Seminar June 17, 2024
:::

---

## Acknowledgements

Stéphanie, Anne-Kristin, You all!, NORMENT, Patients enrolled in the TOP Cohort

![](img/Martens_web2022final.png){fig-align="center"}

---
